Spruce Biosciences (SPRB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, at 10:00 A.M. Pacific Time, to be held virtually.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting.
Ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Advisory vote on the preferred frequency of future say-on-pay votes, with the board recommending annual votes.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Nominees for Class III director positions: Michael Grey, Camilla V. Simpson, M.Sc., and Javier Szwarcberg, M.D., MPH.
Latest events from Spruce Biosciences
- Q2 2026 net loss was $16.2M as R&D spending surged, with $96.3M in cash and new leadership.SPRB
Q2 2026 - Lead therapy for MPS IIIB nears approval, showing strong efficacy and commercial readiness.SPRB
Jefferies Global Healthcare Conference 2026 - Directors elected, all proposals approved, and strategic plans funded for regulatory milestones.SPRB
AGM 2026 - TA-ERT advances toward BLA submission as finances and leadership strengthen.SPRB
Q1 2026 - Proxy covers director elections, auditor ratification, executive pay, and governance after a 1:75 reverse split.SPRB
Proxy filing - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 2026 - FDA supports accelerated approval; commercial and financial plans are on track for launch.SPRB
Leerink Global Healthcare Conference 2026 - TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends.SPRB
Q4 2025 - TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential.SPRB
Corporate presentation